Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Community-randomized HPV-16/18 vaccination strategy study in Finnish adolescents
2007-001731-55Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, Cervical Cancer (CC) and cervical intraepithelial neoplasia (CIN) (3 arms), sponsored by GSK. Started Jun 2007; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2007-001731-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001731-55.